Stockscreener 앱 받기
29.54
2.07%
0.60
전일 마감가:
$28.94
열려 있는:
$29.06
하루 거래량:
875.40K
Relative Volume:
1.12
시가총액:
$1.96B
수익:
$5.79M
순이익/손실:
$-199.61M
주가수익비율:
-9.814
EPS:
-3.01
순현금흐름:
$-188.48M
1주 성능:
-4.15%
1개월 성능:
+21.71%
6개월 성능:
+29.68%
1년 성능:
+47.70%
1일 변동 폭
$28.95
$30.14
1주일 범위
$28.72
$31.31
52주 변동 폭
$14.40
$31.31
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
29.54 | 1.92B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-13 | 개시 | Barclays | Underweight |
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Propel Bio Management LLC Makes New $4.01 Million Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Segall Bryant & Hamill LLC Buys 140,709 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Exploring an 83.57% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
The Goldman Sachs Group Increases Celldex Therapeutics (NASDAQ:CLDX) Price Target to $34.00 - MarketBeat
Q3 Earnings Forecast for CLDX Issued By HC Wainwright - MarketBeat
Celldex Presents Positive Data Demonstrating Barzolvolimab - GlobeNewswire
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory - Insider Monkey
Celldex Stock Pre-Market (-4.7%): Profit-Taking After Positive Phase 2 Data Presentation - Trefis
Assessing Celldex Therapeutics (CLDX) Valuation After Positive Barzolvolimab Phase 3 Enrollment And Phase 2 Data - Sahm
Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential - Yahoo Finance
Celldex presents phase 2 data for chronic urticaria treatment By Investing.com - Investing.com Canada
Celldex Presents Additional Positive Data from Phase 2 - GlobeNewswire
What is HC Wainwright's Forecast for CLDX Q1 Earnings? - MarketBeat
CLDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results - MarketBeat
Celldex Therapeutics Rallied 24% After Clinical Update: Here’s What Analysts See Next - TIKR.com
Celldex Therapeutics stock earns 88 RS rating - MSN
Celldex Therapeutics Hits Day High with 24% Surge in Stock Price - Markets Mojo
Celldex Therapeutics Hits New 52-Week High at $31.00 - Markets Mojo
Celldex Therapeutics stock hits 52-week high at 30.66 USD By Investing.com - Investing.com India
November 20th Options Now Available For Celldex Therapeutics (CLDX) - Nasdaq
Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from Stifel Nicolaus - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Hits New 52-Week HighHere's What Happened - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CLDX Technical Analysis & ETF Price Forecast - Intellectia AI
CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent - Stocktwits
Celldex Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Celldex: Fourth Quarter Financial Overview - Bitget
Celldex: Q4 Earnings Snapshot - marketscreener.com
Celldex Therapeutics stock hits 52-week high at 30.66 USD - Investing.com
Celldex Therapeutics Opens with a 6.56% Gain, Outpacing S&P 500's 0.69% Increase - Markets Mojo
Celldex Therapeutics, Inc. SEC 10-K Report - TradingView
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics Hits Day High with Strong 7.91% Intraday Surge - Markets Mojo
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q4 Revenue $0.1M, vs. FactSet Est of $1.3M - marketscreener.com
Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Celldex Therapeutics Completes Enrollment in Phase 3 Studies of Barzolvolimab; Shares Rise - marketscreener.com
Celldex surges after completing enrollments in late-stage trials for lead asset - Seeking Alpha
Celldex Therapeutics Completes Enrollment in Phase 3 Studies of Barzolvolimab in Chronic Spontaneous Urticaria - marketscreener.com
Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule - Investing.com Canada
Celldex Therapeutics has successfully completed patient enrollment for its two global Phase III clinical studies—Embarq-Csu1 and Embarq-Csu2—of the innovative drug Barzolvolimab for chronic spontaneous urticaria. - Bitget
Celldex completes enrollment in global Phase 3 studies (Embarq-Csu1 and Embarq-Csu2) of barzolvolimab in chronic spontaneous urticaria - marketscreener.com
Celldex Completes Enrollment in Global Phase 3 Studies - GlobeNewswire
Earnings Update: Will FTB PRACL benefit from sector rotationWeekly Market Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Analysis Recap: How correlated is Celldex Therapeutics Inc to the S P500July 2025 Gainers & Accurate Intraday Trading Signals - baoquankhu1.vn
Can Celldex Therapeutics Inc disrupt its industryJuly 2025 Price Swings & Stock Market Timing Techniques - baoquankhu1.vn
Celldex Therapeutics (CLDX) Investor Outlook: Exploring the 119% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Celldex Therapeutics, Inc.Common Stock (NQ: CLDX - The Chronicle-Journal
Celldex Therapeutics (NASDAQ:CLDX) Trading 6.3% HigherStill a Buy? - MarketBeat
Celldex Announces Multiple Upcoming Presentations at AAAAI - GlobeNewswire
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):